Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secodary hyperparathyroidism

Nephrology Dialysis Transplantation

Volumn 18, Issue 12, 2003, Pages 2613-2621

  Okuno, Senji ^a   Ishimura, Eiji ^a   Kitatani, Kayoko ^a   Chou, Hidenori ^a   Nagasue, Kyoko ^a   Maekawa, Kiyoshi ^a   Izumotani, Tsuyoshi ^a   Yamakawa, Tomoyuki ^a   Imanishi, Yasuo ^a   Shoji, Tetsuo ^a   Inaba, Masaaki ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Maxacalcitol; Parathyroid hormone; Secondary hyperparathyroidism; Ultrasonography

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HEMODIALYSIS; HUMAN; MALE; ORGAN SIZE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ANTIMETABOLITES; BODY WEIGHTS AND MEASURES; CALCITRIOL; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PARATHYROID GLANDS;

EID: 10744230203     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg451     Document Type: Article

References (22)

1. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55: 299-307
2. Fukagawa M, Kazama JJ, Shigematsu T. Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. Nephrol Dial Transplant 2002; 17: 1553-1557
3. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
4. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 1996; 11 [Suppl 3]: 121-124
5. Kubrusly M, Gagne ER, Urena P et al. Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 1993; 44: 551-556
6. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001; 38: S147-S151
7. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35: 458-464
8. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68: 221-228
9. Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis 1996; 28: 704-712
10. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
11. Katoh N, Nakayama M, Shigematsu T et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000; 35: 465-468
12. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
13. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631
14. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166
15. Shoji S, Nishizawa Y, Tabata T et al. Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy. Miner Electrolyte Metab 1995; 21: 223-228
16. Silver J, Sela SB, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 1997; 6: 321-326
17. Indridason OS, Heath H,III, Khosla S, Yohay DA, Quarles LD. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int 1996; 50: 1663-1671
18. Chou H, Inaba M, Nishizawa Y et al. Case of a parathyroidectomized patient observed longitudinally by ultrasonography. Relationship between the growth rates and 1,25-dihydroxyvitamin D3 receptor contents in the parathyroid glands. Nephron 1996; 73: 695-700
19. Canalejo A, Almaden Y, Torregrosa V et al. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol 2000; 11: 1865-1872
20. Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K. Medical and surgical aspects of parathyroidectomy. Kidney Int Suppl 1999; 73: S65-S69
21. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
22. Kakuta T, Fukagawa M, Fujisaki T et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999; 33: 1091-1099